| Total: $509.87M | ||||
| Company | Type Of Financing | Number | Amount Raised (M) | Investors; Placement Agents; Details |
| | ||||
| AlphaRx | Private placement of common stock and warrants | N/A | $0.5 | AlphaRx raised $500,000 through an interim unit financing conducted by Greystone Mercantile Bancorp Ltd. (10/16) |
|
| ||||
| AltaRex | Private placement of special units | 7.2U | C$12.6 | AltaRex raised US$8M in the private placement led by Yorkton Securities Inc.; the syndicate also includes Wells Fargo Van Kasper; each unit entitles the holder to acquire one common share and one warrant to purchase one share at C$2 (10/23) |
|
| ||||
| Arius | Rights offering | 0.756S | C$2.65 (US$1.7) | Arius raised US$1.7M in a rights offering of 756,000 common shares (10/9) |
|
| ||||
| Avant Immuno- | Private placement of common stock | 3S | $14 | Avant raised $14M in the sale of 3M shares that were part of a shelf registration filed in July; Ladenburg Thalmann & Co. acted as placement agent (10/17) |
|
| ||||
| Biomira Inc. | Private placement of convertible debentures and warrants | W for 0.75S | $15 | Biomira raised $15M in the private placement; the debentures may be converted into Biomira common shares at holders' options for $6 each, with maturity at 22 months; warrants for 750,000 common shares were issued to the debenture holders at a fixed price of $6, with the term expiring Dec. 31, 2004 (10/1) |
|
| ||||
| Cubist | Private placement of subordinated notes | N/A | $125 | Cubist raised $125M by offering 5.5%, seven-year subordinated notes, due in 2008 and convertible into Cubist common stock; the notes were sold to institutional buyers (10/23) |
|
| ||||
| Discovery | Private placement of units | U consisting of 3.5S and W for 0.7S | $7.7 | Discovery Laboratories completed a private placement, raising about $7.7M; it sold units consisting of about 3.5M shares of common stock and warrants to purchase about 700,000 shares (10/3) |
|
| ||||
| MGI Pharma | Private placement of common stock | 3S | $31 | MGI Pharma raised $31M in a private placement with institutional investors; U.S. Bancorp Piper Jaffray acted as placement agent (10/31) |
|
| ||||
| Nastech | Private placement of common stock | 1.1S | $5.8 | Nastech raised about $5.8M in a private financing; Dain Rauscher Wessels acted as exclusive placement agent; investors were Safeco Growth and RST Opportunities Fund, MPM Capital BioEquities Fund, Perceptive Life Sciences Fund and RS Investments Growth Fund (10/18) |
|
| ||||
| Organo- | Private placement of convertible subordinated notes and common stock | 2.17S | $20.25 | Organogenesis raised $10M from the sale of 7% convertible subordinated notes to Novartis Pharma AG; it raised an additional $10.25M with the sale of 2.17M shares to institutional investors, directors of the company and other individuals (10/16) |
|
| ||||
| Paradigm | Private placement of common stock | 5.1S | $28 | Paradigm Genetics raised $28M through the placement of 5.1M shares at $5.50 per share with JP Morgan H&Q; the deal is pursuant to a $75M shelf registration filed in September (10/17) |
|
| ||||
| ReGen | Private placement of common stock | 10.5S | #1 (US | ReGen conditionally placed 10.5M shares at 10 pence each, raising about US$1.42M (10/24**) |
|
| ||||
| Regeneron | Private placement of seven-year convertible notes | N/A | $200 | Regeneron placed the notes, which will accrue interest at 5.5% annually and have a conversion price of $30.25; purchasers of the stock have an option to buy another $50M in principal amount of notes (10/12) |
|
| ||||
| Siga Tech- | Private placement of common stock and warrants | 0.67S and W for 0.33S | $2 | Siga raised $2M in the private placement of 0.67 shares and warrants for another 0.33 shares; the shares and warrants were placed by the Shemano Group (10/12) |
|
| ||||
| Triangle | Private placement of common stock | 18.7S | $49.5 | Triangle sold 18.7M shares of common stock at $2.65 per share to a group of investors led by Warburg Pincus Private Equity VIII LP; Banc of America Securities LLC served as placement agent; this is the second closing of a financing begun in August (10/11) |
| | ||||
| Notes: | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
| ** Denotes the date the item ran in BioWorld International. | ||||
| @ Dates refer to the date of the press release. |
||||
| N/A = Not available, applicable or reported. |
||||
| AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
